Longitudinal assessment of BMI in relation to ADT use among early stage prostate cancer survivors
The use of androgen deprivation therapy (ADT) for prostate cancer is on the rise, but its adverse side effects may include increased fat mass and decreased lean muscle mass. The net effect of ADT on BMI is unknown.
Primary, incident cases of early stage prostate cancer (n = 473) were identified from the Buffalo VA Medical Center tumor registry and matched to body size, demographic, comorbidity, and treatment exposure data from veteran medical records. Multilevel modeling was used to assess the association between ADT and changes in BMI.
On average, survivors were overweight at diagnosis and showed small, non-significant changes in BMI over time. However, among those survivors with a history of ADT, a significant decrease of 0.05 BMI units per year was associated with each additional dose of ADT (p < 0.001). When the association between BMI rate of change and ADT was allowed to vary with respect to age, additional doses of ADT predicted stronger decreases in BMI for younger survivors as compared to older survivors (p < 0.05). Neither a history of surgery nor radiation influenced the association between ADT use and BMI.
Declines in BMI in relation to ADT exposure may be reflective of unfavorable changes in body composition, especially decreased muscle mass, that is most pronounced in younger survivors.
Implications for Cancer Survivors
Survivors on ADT may benefit from close monitoring of physical functioning and referral for exercise interventions to preserve muscle mass and improve health related quality of life.
KeywordsAndrogen deprivation therapy Body mass index Cancer survivorship Longitudinal studies Prostatic neoplasms
- 1.Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975–2004. 2007. Based on November 2006 SEER data submission.Google Scholar
- 2.VA National Tumor Registry. Consolidated Data Summary Report. http://vaww1.va.gov/cancer/docs/SUMM2006.doc. Accessed December, 2008.
- 7.Mohile SG, Mustian K, Bylow K, et al. Management of complications of androgen deprivation therapy in older men. Crit Rev Oncol/Hematol. 2009;70(3):235–55.Google Scholar
- 13.Stroup SP, Cullen J, Auge BK, et al. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix Consensus Definition. Cancer. 2007;110:1003–8.CrossRefPubMedGoogle Scholar
- 15.Rodriguez C, Patel AV, Calle EE, et al. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomark Prev. 2001;10:345–53.Google Scholar
- 26.NCI. Facing forward: Life after cancer treatment. http://www.cancer.gov/cancertopics/life-after-treatment/page3#b3. Accessed December, 2008.
- 28.SAS Institute Inc., SAS 9.2. Cary, NC: 2002–2008.Google Scholar
- 33.Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass, and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167:2361–7.CrossRefPubMedGoogle Scholar